AZTR AMEX
Azitra, Inc.
1W: +14.6%
1M: -0.9%
3M: +26.5%
YTD: -23.9%
1Y: -89.2%
$0.20
-0.01 (-3.82%)
Weekly Expected Move ±10.5%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$2.2M
52W Range0.1-2.4
Volume528,373
Avg Volume11,913,377
Beta-1.39
Dividend—
Analyst Ratings
Company Info
CEOFrancisco D. Salva
Employees12
SectorHealthcare
IndustryBiotechnology
IPO Date2023-06-20
Websiteazitrainc.com
21 Business Park Drive
Branford, CT 06405
US
Branford, CT 06405
US
203 646 6446
About Azitra, Inc.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Staskey Norm | A-Award | 35,524 | $0.21 | 2026-04-20 |
| Salva Francisco D. | A-Award | 220,879 | $0.21 | 2026-04-20 |
| Whitfill Travis | A-Award | 64,300 | $0.21 | 2026-04-20 |
| Salva Francisco D. | P-Purchase | 4,064,050 | $0.12 | 2026-03-18 |
| Salva Francisco D. | P-Purchase | 4,064,050 | $0.12 | 2026-03-18 |